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responses to FSH in women with polycystic
ovary syndrome
Michael V. Homer1, Marcus A. Rosencrantz2, Rana F. Shayya3 and R. Jeffrey Chang1,4*Abstract
Background: The influence of estradiol (E2) on granulosa cell (GC) function has not been tested clinically in women
with polycystic ovary syndrome (PCOS). The objective of this study is to determine if E2 influences GC responses to
FSH in women with PCOS.
Methods: This is a two phase, single cohort study conducted over a 2-year period at a single academic center.
Nine women with PCOS according to NIH criteria. In Phase 1, FSH stimulation of GC responses as measured by E2
and Inhibin B (Inh B) were assessed before and at 5 and 6 weeks after GnRH agonist administration. In Phase 2, the
same protocol was employed with the addition of an aromatase inhibitor (letrozole, LET) administered daily
beginning at week 4 for 2 weeks.
Results: In Phase 1, recovery of FSH, E2 and Inh B from ovarian suppression occurred at 5 and 6 weeks after GnRH
agonist injection and preceded resumption of LH and androgen secretion. In Phase 2, hormone recovery after
GnRH agonist was characterized by elevated FSH and suppressed E2 levels whereas recovery of LH and androgen
levels were unchanged. In Phase 1, FSH stimulated E2 and Inh B responses were unaltered during recovery from
ovarian suppression. In Phase 2, E2 and Inh B fold changes after FSH were significantly reduced at weeks 5 (p < 0.04)
and 6 (p < 0.01), respectively.
Conclusion: In anovulatory women with PCOS, chronic, unopposed E2 secretion may contribute, at least in part, to
enhanced ovarian responsiveness to FSH.
Trial registration: NCT02389088
Keywords: Polycystic ovary syndrome, Granulosa cell, Estradiol, FSH, Inhibin BBackground
The characteristic features of polycystic ovary syndrome
(PCOS) are anovulation, androgen excess, and polycystic
ovary morphology. Anovulation is associated with modest
estradiol (E2) secretion derived primarily from peripheral
extraglandular conversion and minimal progesterone pro-
duction. However, in vitro and in vivo studies have dem-
onstrated that granulosa cells (GCs) from women with
PCOS are hyperresponsive to FSH stimulation compared
to responses observed in normal GCs. These findings* Correspondence: rjchang@ucsd.edu
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women with this disorder [1–3].
Local production of E2 may account, at least in part,
for the enhanced CG response to FSH in PCOS. There
is considerable evidence that estrogen enhances follicle
function including responses to FSH. Diethylstilbestrol
treated GCs from immature hypophysectomized rats
produced greater E2 release in response to FSH com-
pared to that of untreated cells [4]. In addition, estrogen
has been shown to influence GC cytodifferentiation by
modulating follicular intracellular gap junctions, estrogen
receptor content, and adenylate cyclase activity [5–7].
Synergy between E2 and FSH has been demonstrated in
GCs with regards to increased FSH receptor binding and
increased aromatase activity [8–10]. Correspondingle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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GC E2 production in women has been understandably
difficult and not undertaken.
Previously, we and others have shown that in women
with PCOS serum E2 and inhibin B (Inh B) exhibit similar
temporal responsiveness to FSH [11, 12]. These findings
suggest that Inh B may serve as a marker of granulosa cell
activity alongside E2. In an effort to determine whether
estrogen influences GC function in women with PCOS,
we examined Inh B responses to FSH in the presence or
absence of an aromatase inhibitor.
Methods
Participants
Nine women with PCOS were recruited for study. All
subjects were between 18 and 35 years of age and exhib-
ited clinical and laboratory evidence of hyperandrogenism,
were either oligomenorrheic or amenorrheic and had
greater than 12 antral follicles per ovary on transvaginal
ultrasound that are consistent with criteria established by
the NIH, Rotterdam, and Androgen Excess-PCOS Society.
Mean age (± SE) was 26 ± 1.2 years and BMI (± SE) was
33.7 ± 2.4 kg/m2. Serum levels of 17-hydroxyprogesterone
(17-OHP), TSH, and prolactin were within normal range.
All patients were free of medication containing hormones
for 3 months or greater prior to study.
The study was approved by the Human Research Pro-
tection Program at the University of California, San
Diego (UCSD, IRB#100023) and written informed con-
sent was obtained from each participant before study.
Procedures
The study was divided into two phases. For Phase I of
the study, participants were admitted on a random day
to the Clinical and Translational Research Institute
(CTRI) at UC San Diego for testing. Patients all had
serum progesterone levels < 1.5 ng/ml and negative hCG
tests. After placement of an intravenous line, each sub-
ject received an intravenous injection of recombinant
human FSH (r-hFSH), 150 IU. Blood samples were ob-
tained prior to and 24 h afterwards. After the last blood
sample was obtained, each was given long-acting GnRH
agonist (Depot Lupron), 3.75 mg intramuscularly, to
maximally suppress ovarian steroid production for one
month after which serum E2 levels gradually resume
[13]. Ovarian suppression was employed to allow for
FSH stimulation studies to be conducted during the
recovery phase when the ovary and GCs regain respon-
siveness, thereby establishing uniform and comparable
E2 levels in both phases of study. During this interval,
FSH stimulation was repeated at the end of week 5 and
week 6.
For Phase II of the study, the same 9 participants were
allowed to have a hormone-free washout period of3 months from administration of GnRH agonist and
2 months from the prior dose of FSH. They were then
re-admitted to the CTRI at UC San Diego for study.
Similar to Phase I, they underwent a baseline FSH
stimulation test after which 3.75 mg of Depot Lupron
was administered. At the beginning of week 4, each sub-
ject received an aromatase inhibitor, Letrozole (LET),
5 mg daily, for 2 weeks to restrict increases of serum
E2 levels that were observed in Phase I. The FSH
stimulation test was then repeated at the end of week
5 and week 6.
Assays
Serum concentrations of LH and FSH were measured by
radio-immunoassay (RIA) with intra— and inter-assay
coefficients of variation (CV) of 5.4 and 8.0%, respect-
ively, for LH and 3.0 and 4.6%, respectively, for FSH
(Diagnostic Products Corp., Los Angeles, CA, USA).
Serum concentrations of Inh B were measured by ELISA
with inter— and intra-assay CV of 6.7 and 4.6% (Diag-
nostic Systems Laboratories, Inc., Webster, TX, USA).
The highly specific two-site ELISA Kit allows for quanti-
tative measurement of dimeric Inh B in human serum.
Assay sensitivity for Inh B was 7.0 pg/ml. Serum concen-
trations of E2, androstenedione (A) and testosterone (T)
were measured by well-established RIA with intra-assay
CV less than 7%. P4, 17-OHP and dehydroepiandrosterone
sulfate (DHEAS) were measured by RIA with intra-assay
CV less than 7% (Diagnostic Systems Laboratories, Inc.,
Webster, TX, USA).
Statistical analysis
Q-Q plot and boxplot were used to check the normality
of the data. One-sample t-test and one-sample Wilcoxon
signed-rank test were applied as needed to test the dif-
ferences of hormone measurements at both baseline and
after FSH stimulation for Phase I compared to Phase II.
We also tested for differences in the log fold change of
E2, Inh B and insulin hormone before and after FSH. For
all analysis, p values of < 0.05 were considered statisti-
cally significant. Statistical analysis were performed using
the R statistical computing software (version 2.6.2,
http://www.r-project.org, 2009).
Results
Serum hormone levels before and after GnRH agonist
ovarian suppression (phase I)
Baseline circulating hormone levels for women with
PCOS are shown in Table 1. Mean circulating levels of
LH, FSH, A, T, E2 and Inh B before and following pituit-
ary gonadotropin desensitization and ovarian suppres-
sion are shown in Fig. 1. As expected, serum E2 levels at
the end of week 5 and week 6 after GnRH agonist ap-
proximated pretreatment levels that reflected recovery
Table 1 Baseline circulating steroid hormone and gonadotropin
levels in women with PCOS.
PCOS (n = 9)
LH (IU/L) 9.01 [5.95 – 12.87]
FSH (IU/L) 4.98 [4.36 – 5.48]
T (nmol/L) 1.3 [1.17 – 1.54]
A (nmol/L) 4.84 [4.55 – 6.52]
17OH-P (nmol/L) 46.36 [34.85 – 49.39]
E2 (pmol/L) 179 [158–204]
Data are expressed as Median [IQ Range]). To convert to gravimetric units,
multiply by the following conversion factors: T [ng/dL], 28.82; A [ng/dL], 28.65;
17OH-P [ng/dL], 3.30; E2 [pg/mL], 0.27
Fig. 1 Serum hormone levels before and during recovery from GnRH
agonist. Serum levels of FSH (IU/L), LH (IU/L) T (nmol/L), A (nmol/L), E2
(pmol/L) and Inh B (ng/L)
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of 5 and 6 weeks after GnRH agonist were not different
compared to baseline serum values. Serum FSH levels at
the end of week 5 were similar to baseline concentrations
indicating complete recovery from pituitary desensitization.
By comparison, LH and serum androgens at the end of
week 5 remained lower than pre-GnRH agonist treatment
levels. Subsequently, there were subtle increases of LH and
androgen production by the end of week 6.
Serum hormone levels before and after GnRH agonist
ovarian suppression in the presence of LET (phase II)
In Phase II, corresponding levels of gonadotropins, E2,
Inh B and androgens associated with the administration
of LET during weeks 4 and 5 after GnRH agonist injec-
tion are shown in Fig. 2. Basal E2 levels were signifi-
cantly lower during daily LET administration (weeks 5
and 6) compared to corresponding values observed in
Phase 1. Accordingly, these reduced E2 levels were asso-
ciated with significantly higher basal serum FSH levels at
week 5 and 6 (p < 0.01) as shown in Fig. 2. Notably,
these increments of FSH were significantly greater than
those observed without LET. In contrast to E2, basal
serum Inh B levels exhibited increases during LET treat-
ment compared to the mean baseline value at week 0,
although these increments were not statistically signifi-
cant. In Phase 2 patterns of increasing basal values of
LH, A and T levels during recovery were similar to those
observed in Phase 1.
E2 and Inh B responses to FSH during recovery from
GnRH suppression in the absence and presence of LET
In Phase I, the FSH-stimulated fold-changes of E2 at 5
and 6 weeks during recovery were not significantly dif-
ferent from that observed at baseline, prior to GnRH
agonist administration (Table 2). However, in Phase II
studies with LET treatment, reduced basal E2 levels were
accompanied by a corresponding decline of the fold-
change E2 responses to FSH injection at weeks 5 (p < 0.04)
and 6 (p < 0.01) compared to baseline. Similarly, Inh B
responses to FSH in were not different in Phase I, but
significantly decreased fold-changes following FSH were
observed at 5 (p < 0.04) and 6 (p < 0.01) weeks.
Discussion
The results of this study are consistent with a facilitative
role for E2 on GC function in women with PCOS. This
is suggested by the reduced fold-change responses of
Inh B as well as E2 following FSH administration in the
presence of lowered serum E2 levels during LET admin-
istration. Decreased responsiveness of Inh B was
observed despite corresponding increases of FSH, which
is known to enhance Inh B release.
Fig. 2 Serum hormone levels before and during recovery from GnRH
agonist together with LET. Serum levels of FSH (IU/L), LH (IU/L) T (nmol/
L), A (nmol/L), E2 (pmol/L) and Inh B (ng/L)
Table 2 Serum estradiol and Inh B fold-change responses to
FSH at week 0 (baseline), week 5 and week 6 during Phase I
(without LET) and Phase II (with LET) of study
Week 0 Week 5 Week 6
Estradiol
Phase I 2.53 ± 0.25 2.14 ± 0.24 2.70 ± 0.27
Phase II 2.20 ± 0.18 1.39 ± 0.16a 1.63 ± 0.20b
Inh B
Phase I 5.31 ± 0.55 5.82 ± 0.88 6.08 ± 0.78
Phase II 5.50 ± 0.25 3.33 ± 0.48a 3.14 ± 0.43b
ap < 0.04, significantly different from Week 0
bp < 0.01, significantly different from Week 0
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with PCOS is a well-recognized phenomenon that
predisposes to hyperstimulation during ovulation induc-
tion. This is likely due to the abundance of small antral
follicles that exist in women with PCOS as well as an
increased number of FSH receptors per granulosa cell in
follicles from anovulatory women with this disorder
[14, 15]. However, there is a lack of clinical studies in
women regarding the role of E2 on GC function and
follicle development. As a result, most of our under-
standing of how E2 impacts follicle health has been
inferred from experiments in animal models. It is ap-
parent that E2 does not exert a direct effect on GCs
as E2 response elements have not been identified on
the CYP19 promoter in the rat model or human GCs
[16]. Rather, it is likely synergism between E2 and
FSH that promotes GC function and follicle growth.
For instance, studies have shown that maximal FSH
stimulation of aromatase activation, antrum formation, and
LH responsiveness in GCs requires E2 [4, 16–20]. These
findings are underscored by studies conducted in β-
estrogen receptor knock out mice that demonstrate the ne-
cessity of E2 to achieve maximum FSH action in GCs [21].
There were modest increases of basal serum Inh B
during LET treatment in Phase II that were not statisti-
cally significant compared to Phase I. The subtle change
of Inh B may have been induced by raised levels of
circulating FSH as a result of lowered serum E2 levels
rather than an inherent increase of GC responsiveness.
Nevertheless, corresponding Inh B responses to FSH
were not greater than those observed prior to GnRH
agonist administration or Inh B responses in Phase I.
Thus, the incremental fold-change was significantly less
in Phase II in association with diminished E2 levels.
Considering that Inh B may serve as a GC marker, this
provides indirect evidence that estrogen augments E2
responsiveness to FSH in women with PCOS.
While these results suggest that E2 may contribute to
enhanced GC function in women with PCOS, it is less
clear as to whether chronic E2 secretion directly impacts
GC hyper-responsiveness to FSH as demonstrated
in vitro or in women with this disorder. In the hypogo-
nadotropic hypogonadal female, serum E2 levels are low
and initial ovarian responses to exogenous FSH are de-
creased compared to anovulatory women with normal
E2 concentrations. Estradiol has also been used in poor
ovarian responders to help increase the number of ma-
ture follicles retrieved and decrease cycle cancellations
[22]. By comparison, anovulatory women with PCOS are
distinctive in that efforts to induce ovulation appear to
assume varying and, at times, apparent diametrical ovar-
ian responses. In PCOS women initiation of ovulation
induction has been characterized by a lack of follicle
response that commonly warrants higher therapeutic
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been reported that during clomiphene citrate adminis-
tration significantly smaller increments of E2 were ob-
served compared to those of normal women despite
comparable increases of serum FSH [23] As a result,
several modified treatment regimens have been proposed
that markedly increase the total dose of clomiphene or
utilize additional drugs, including gonadotropins, to en-
hance clomiphene effectiveness. Primary gonadotropin
therapy in women with PCOS has also been associated
with poor initial ovarian responses to ovulation induction
as early E2 responses to daily gonadotropin stimulation
were considerably less compared to that found in normal
women [24]. The mechanism of ovarian insensitivity in the
early stages of ovulation induction has not been examined.
In women with PCOS, chronic E2 secretion has been at-
tributed to peripheral extra-glandular conversion and local
intra-ovarian production may be insufficient to support
early follicular responses to FSH. Alternatively, multiple
factors, both intra- and extra-ovarian, may be responsible
for or contribute to anovulation in women with this dis-
order and warrant further investigation. This would
include AMH’s possible role in regulation of ovarian func-
tion and morphology [25, 26].
Despite the reduction of E2 during LET treatment, cir-
culating levels of T and A were inexplicably not altered.
Whether this was the result of LET superimposed on
already suppressed ovarian steroidogenesis is uncertain,
although it would seem that aromatase inhibition at
extra-glandular sites might result in elevated serum
androgens. Previously, it was reported that T as well as
gonadotropins were unaltered in premenopausal women
administered LET, 2.5 mg, daily over 12 weeks [27].
Another consideration may be that our study subjects
were comprised of only those with PCOS with an
elevated BMI and the results should not be generalized
to a non-obese population due to BMI’s influence on
insulin resistance and ovarian hormones.
The experimental design of our study was complex,
but necessary in an attempt to fully assess the effect of
serum E2 reduction on GC function. Our previously
studies have demonstrated that GnRH agonist adminis-
tration may lower, but not eliminate serum E2 levels in
normal and PCOS women, particularly those with in-
creased BMI as was the case with our study subjects
[12]. To maintain reduced levels of E2 following ovarian
suppression LET was employed during the interval of
ovarian recovery. Use of an anti-estrogen such as a se-
lective E2 receptor modulator may have been considered,
although these compounds may bind to E2 receptors
and activate signaling pathways independent of E2. In
addition, the degree to which E2 action was reduced
would be unclear and measurement of E2 levels would
be of questionable value.Clinical studies to examine the role of estrogen on GC
function in PCOS or normal women have not been per-
formed previously. However, the interpretation of our
results warrants some caution due to the following limi-
tations. First, there were a limited number of subjects
that served as their own controls. Second, non-PCOS
women were not included. Third, the stimulatory dose
of FSH was relatively high and GC responses may have
been maximally stimulated that precluded differential
Inh B production. Fourth, in light of ovarian suppression
by GnRH agonist, LET administration may have been
extended to allow a lengthier recovery prior to FSH
stimulation. This is unlikely as our previous studies as
well as the current results suggest that adequate ste-
roidogenesis had been reestablished by the time of FSH
testing. Lastly, we elected to employ Inh B as a marker of
GC responsiveness to FSH as suggested by Dokras, et. al
[11]. This assumption was based on the parallelism of Inh
B and E2 responses to variable doses of iv FSH in both
normal and PCOS women as previously reported [12].
Conclusions
In summary, the results of this study have demonstrated
that in women with PCOS Inh B responses to FSH are
reduced in the presence of lowered circulating E2 levels.
These finding provide indirect evidence that E2 may
enhance follicle function in women with this disorder.
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